Literature DB >> 24327583

Induced interleukin-33 expression enhances the tumorigenic activity of rat glioma cells.

Kuan-Min Fang1, Chung-Shi Yang, Tzu-Chien Lin, Ti-Chun Chan, Shun-Fen Tzeng.   

Abstract

BACKGROUND: Glioma development is a multistep process associated with progressive genetic alterations but also regulated by cellular and noncellular components in a tumor-associated niche.
METHODS: Using 2 rat C6 glioma cell clones with different tumorigenesis, named C6-1 and C6-2, this study characterized genes associated with enhanced tumorigenic features of glioma cells by comparative cDNA microarray analysis combined with Q-PCR. Neurospehere formation and clonogenicity were examined to determine the growth of tumorigenic C6 glioma cells. The lentivirus-mediated gene knockdown approach was conducted to determine the role of interleukin-33 (IL-33) in glioma cell proliferation and migration. Transwell cell invasion assay was used to examine microglia migration induced by tumorigenic C6 cells.
RESULTS: The functional analysis of gene ontology (GO) biological processes shows that the upregulated genes found in tumorigenic C6 (C6-1) cells are closely related to cell proliferation. Tumorigenic C6 cells expressed cytokines and chemokines abundantly. Among these genes, IL-33 was profoundly induced in tumorigenic C6 cells with the expression of IL-33 receptor ST2. Furthermore, the growth rate and colony formation of tumorigenic C6 cells were attenuated by the inhibition of IL-33 and ST2 gene expression. Moreover, IL-33 was involved in tumorigenic glioma cell migration and regulation of the expression of several glioma-associated growth factors and chemokines in tumorigenic C6 cells.
CONCLUSION: Accordingly, we concluded that glioma cells with abundant production of IL-33 grow rapidly; moreover, the interactions of multiple cytokines/chemokines induced by glioma cells may develop a microenvironment that facilitates microglia/macrophage infiltration and fosters glioma growth in the brain.

Entities:  

Keywords:  ST2; chemokine (C-C motif) ligand 7; glioma; interleukin-33; microglia

Mesh:

Substances:

Year:  2013        PMID: 24327583      PMCID: PMC3956351          DOI: 10.1093/neuonc/not234

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  50 in total

Review 1.  Cyclooxygenase-2: a therapeutic target.

Authors:  Marco E Turini; Raymond N DuBois
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

Review 2.  Understanding the role of cytokines in Glioblastoma Multiforme pathogenesis.

Authors:  Vivian F Zhu; Jingxuan Yang; Drake G Lebrun; Min Li
Journal:  Cancer Lett       Date:  2011-11-07       Impact factor: 8.679

3.  CXCR4 engagement promotes dendritic cell survival and maturation.

Authors:  Kenji Kabashima; Kazunari Sugita; Noriko Shiraishi; Hirokazu Tamamura; Nobutaka Fujii; Yoshiki Tokura
Journal:  Biochem Biophys Res Commun       Date:  2007-07-30       Impact factor: 3.575

4.  Production and functions of IL-33 in the central nervous system.

Authors:  Satoko Yasuoka; Jun Kawanokuchi; Bijay Parajuli; Shijie Jin; Yukiko Doi; Mariko Noda; Yoshifumi Sonobe; Hideyuki Takeuchi; Tetsuya Mizuno; Akio Suzumura
Journal:  Brain Res       Date:  2011-02-22       Impact factor: 3.252

5.  Expression of macrophage inflammatory protein-1α and monocyte chemoattractant protein-1 in glioma-infiltrating microglia: involvement of ATP and P2X₇ receptor.

Authors:  Kuan-Min Fang; Ying-Lan Wang; Ming-Chao Huang; Synthia H Sun; Henrich Cheng; Shun-Fen Tzeng
Journal:  J Neurosci Res       Date:  2010-12-08       Impact factor: 4.164

Review 6.  Role of microglia in the central nervous system's immune response.

Authors:  Wolfgang J Streit; Jessica R Conde; Sarah E Fendrick; Barry E Flanary; Christopher L Mariani
Journal:  Neurol Res       Date:  2005-10       Impact factor: 2.448

Review 7.  What role(s) for TGFalpha in the central nervous system?

Authors:  M P Junier
Journal:  Prog Neurobiol       Date:  2000-12       Impact factor: 11.685

8.  CCR5-binding chemokines modulate CXCL12 (SDF-1)-induced responses of progenitor B cells in human bone marrow through heterologous desensitization of the CXCR4 chemokine receptor.

Authors:  Marek Honczarenko; Yi Le; Aleksandra M Glodek; Marcin Majka; James J Campbell; Mariusz Z Ratajczak; Leslie E Silberstein
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

9.  Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival.

Authors:  Xiu-wu Bian; Shi-xin Yang; Jian-hong Chen; Yi-fang Ping; Xiang-dong Zhou; Qing-liang Wang; Xue-feng Jiang; Wanghua Gong; Hua-liang Xiao; Lin-lin Du; Zi-qiang Chen; Wen Zhao; Jing-quan Shi; Ji Ming Wang
Journal:  Neurosurgery       Date:  2007-09       Impact factor: 4.654

10.  Tetramethylpyrazine inhibits activities of glioma cells and glutamate neuro-excitotoxicity: potential therapeutic application for treatment of gliomas.

Authors:  Yu-Show Fu; Yen-Yang Lin; Shih-Chich Chou; Tung-Hu Tsai; Lung-Sen Kao; Shao-Yun Hsu; Fu-Chou Cheng; Yang-Hsin Shih; Henrich Cheng; Yu-Yi Fu; Jia-Yi Wang
Journal:  Neuro Oncol       Date:  2008-02-26       Impact factor: 12.300

View more
  25 in total

1.  Functional Role of Matrix gla Protein in Glioma Cell Migration.

Authors:  Mu-Hui Fu; Chih-Yen Wang; Yun-Ti Hsieh; Kuan-Min Fang; Shun-Fen Tzeng
Journal:  Mol Neurobiol       Date:  2017-07-13       Impact factor: 5.590

2.  Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways.

Authors:  Xiaoguang Tong; Mark Barbour; Kezuo Hou; Chao Gao; Shuang Cao; Jingli Zheng; Yang Zhao; Rong Mu; Hui-Rong Jiang
Journal:  Mol Oncol       Date:  2015-09-09       Impact factor: 6.603

3.  Depletion of B cell CLL/Lymphoma 11B Gene Expression Represses Glioma Cell Growth.

Authors:  Chih-Kai Liao; Kuan-Min Fang; Kitman Chai; Chin-Hsien Wu; Chia-Hsin Ho; Chung-Shi Yang; Shun-Fen Tzeng
Journal:  Mol Neurobiol       Date:  2015-06-23       Impact factor: 5.590

4.  IL-33 induces ADAMTS5 expression and cell migration in glioblastoma multiforme.

Authors:  Dilara Akcora-Yildiz; Yunus Yukselten; Merve Sunguroglu; Hasan Caglar Ugur; Asuman Sunguroglu
Journal:  Med Oncol       Date:  2022-01-04       Impact factor: 3.064

5.  VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells.

Authors:  Yuanyuan Chen; Delong Meng; Huibo Wang; Ruochuan Sun; Dongrui Wang; Shuai Wang; Jiajun Fan; Yingjie Zhao; Jingkun Wang; Song Yang; Cong Huai; Xiao Song; Rong Qin; Tao Xu; Dapeng Yun; Lingna Hu; Jingmin Yang; Xiaotian Zhang; Haoming Chen; Juxiang Chen; Hongyan Chen; Daru Lu
Journal:  Neuro Oncol       Date:  2014-09-10       Impact factor: 12.300

Review 6.  Alarmins and immunity.

Authors:  Zhen Han; Joost J Oppenheim
Journal:  Immunol Rev       Date:  2017-11       Impact factor: 12.988

7.  Pleural Effusion IL-33/sST2 Levels and Effects of Low and High IL-33/sST2 Levels on Human Mesothelial Cell Adhesion and Migration.

Authors:  Ourania S Kotsiou; Rajesh M Jagirdar; Eleftherios D Papazoglou; Chrissi Hatzoglou; Konstantinos I Gourgoulianis; Sotirios G Zarogiannis
Journal:  Inflammation       Date:  2019-12       Impact factor: 4.657

8.  Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.

Authors:  Kit Man Chai; Chih-Yen Wang; Hung-Jiun Liaw; Kuan-Min Fang; Chung-Shi Yang; Shun-Fen Tzeng
Journal:  Oncotarget       Date:  2014-11-15

9.  Transforming growth factor-β pathway activity in glioblastoma.

Authors:  Karl Frei; Dorothee Gramatzki; Isabel Tritschler; Judith Johanna Schroeder; Larisa Espinoza; Elisabeth Jane Rushing; Michael Weller
Journal:  Oncotarget       Date:  2015-03-20

Review 10.  Therapeutic Opportunities of Interleukin-33 in the Central Nervous System.

Authors:  Yun Sun; Yankai Wen; Luxi Wang; Liang Wen; Wendong You; Shuang Wei; Lin Mao; Hao Wang; Zuobing Chen; Xiaofeng Yang
Journal:  Front Immunol       Date:  2021-05-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.